Zymergen's bid to disrupt a $3T industrial manufacturing market goes viral, earning a massive $500M IPO
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
It’s not a story you hear every day: A biotech company that doesn’t use its platform to develop therapeutics? Despite some raised eyebrows early on, Emeryville, CA-based Zymergen has convinced investors that its plan to disrupt industrial manufacturing is worth the bet and now it’s priced an eye-popping IPO to take its mission to the next level.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.